As you may already know, The Lancet recently retracted a May 22 article it published claiming that the generic anti-malaria drug hydroxychloroquine (HCQ) is ineffective against the Wuhan coronavirus (COVID-19). Not only were the claims made in this now-retracted paper false, but it turns out that the very same people who put it together were also busy publishing other studies pushing the anti-viral drug remdesivir as the preferable alternative to HCQ.
A “tiny U.S. based company” named Surgisphere, we reported, had generated “flawed data” that led to the result that its “hidden” authors wanted to see, which is basically that HCQ is useless in terms of remedying the pandemic.
While it initially appeared as though Surgisphere was directly to blame for the fiasco, a closer look at the aforementioned “hidden” authors has revealed Brigham and Women’s Hospital, under the guidance of Harvard University professor Mandeep Mehra, as the true culprit.
Mehra, who currently holds the Harvey Distinguished Chair of Medicine at Brigham and Women’s Hospital, issued an apology for his involvement in the scam, which he claimed was a mistake. But it turns out that Mehra was quietly involved in an elaborate scheme designed to “kill” the legitimacy of HCQ as a cure for the Wuhan coronavirus (COVID-19).
At the very same time that Mehra was working on his fake study, another study, also out of Brigham and Women’s Hospital, was also taking place at the direction of Dr. Francisco Marty, who was working on behalf of Gilead Sciences Inc., the manufacturer of remdesivir, to push its drug instead of HCQ.
“Brigham and Women’s Hospital began enrolling patients in two clinical trials for Gilead’s antiviral medication remdesivir,” a report about the trial explains. “The Brigham is one of multiple clinical trial sites for a Gilead-initiated study of the drug in 600 participants with moderate coronavirus disease (COVID-19) and a Gilead-initiated study of 400 participants with severe COVID-19.”
“If the results are promising, this could lead to FDA approval, and if they aren’t, it gives us critical information in the fight against COVID-19 and allows us to move on to other therapies.”
Though Mehra was not directly involved with this latter study, his colleague Marty was, and they had to both know what was going on because Mehra had participated in a conference sponsored by Gilead back in early April “as part of the Covid-19 debate.”
The rabbit hole goes deep on this one, but suffice it to say that it all happened from the top down, with none other than Anthony Fauci, “America’s top infectious disease expert,” rallying the troops, so to speak. Fauci has played a critical role in smearing HCQ from the beginning, and pushing remdesivir instead.
Keep in mind that Fauci has been heading up the National Institute of Allergy and Infectious Diseases (NIAID) since the Reagan administration. He has been a mouthpiece for Big Pharma this entire time, in other words, and only now has been exposed as the snake he truly is.
“Dr. Fauci launched Remdesivir in late June,” reports Professor Michel Chossudovsky, writing for Global Research (Canada). “According to Fauci, Remdesevir is the ‘corona wonder drug’ developed by Gilead Science Inc. It’s a $1.6 billion dollar bonanza.”
Gilead has been around for a while, by the way. It is currently backed by multiple major investment conglomerates including the Vanguard Group and Capital Research & Management Co., among various others. It is also directly tied to the U.S. government, having worked to develop the infamous Tamiflu drug for influenza that has been linked to serious adverse effects, especially in children.
Donald Rumsfeld, prior to “serving” as the Secretary of Defense under President George W. Bush, used to be the head of Gilead. This is before he helped coordinate the illegal and criminal wars on both Iraq and Afghanistan.
Even while working in the federal government under Bush, Rumsfeld still held shares in Gilead, which saw its shares skyrocket when it was announced that there was a high risk of a bird flu outbreak. This outbreak never actually materialized to the scale of the current Wuhan coronavirus (COVID-19) pandemic, but it still resulted in windfall dividends for shareholders like Rumsfeld.
Fast-forward to today and the same Fauci who back then pulled the strings to help his deep state buddies like Rumsfeld rake in the dough is once again attempting the same thing by facilitating the publishing of fake studies that promote another “blockbuster” Gilead drug while maligning a safer and cheaper generic in the form of hydroxychloroquine.
In a Gilead-sponsored paper that appeared in the New England Journal of Medicine (NEJM), the claim was made that remdesivier works for treating the Wuhan coronavirus (COVID-19). It was co-authored by 56 different medical doctors and scientists, all of whom just so happen to have received “consulting fees” from Gilead.
This is the type of corrupt nonsense that continues to happen under Fauci’s watch, which is why the guy is under increasing scrutiny. It remains to be seen whether the Trump administration will take action to dismantle such corruption, or leave it be to continue raking the general public over the coals when it comes to safe and effective treatments for the Wuhan coronavirus.
Be sure to read the rest of Prof. Chossudovsky’s analysis of the situation at this link.
To keep up with the latest news about the Wuhan coronavirus (COVID-19), be sure to check out Pandemic.news.
Sources for this article include: